nach oben

Erschienen in:

01.07.2008 | Clinical Trial

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

verfasst von: Stephen R. D. Johnston, Vladimir F. Semiglazov, George M. Manikhas, Dominique Spaeth, Gilles Romieu, David J. Dodwell, Andrew M. Wardley, Patrick Neven, Annick Bessems, Youn C. Park, Peter M. De Porre, Juan J. Perez Ruixo, Angela J. Howes

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy.

Patients and methods

Postmenopausal women with estrogen-receptor-positive advanced breast cancer that had progressed after tamoxifen were given 2.5 mg letrozole once daily and were randomly assigned (2:1) to tipifarnib 300 mg (TL) or placebo (L) twice daily for 21 consecutive days in 28-day cycles. The primary endpoint was objective response rate.

Results

Of 120 patients treated with TL (n = 80) or L (n = 40), 113 were evaluable for response. Objective response rate was 30% (95% CI; 20–41%) for TL and 38% (95% CI; 23–55%) for L. There was no significant difference in response duration, time to disease progression or survival. Clinical benefit rates were 49% (TL) and 62% (L). Tipifarnib was generally well tolerated; a higher incidence of drug-related asymptomatic grade 3/4 neutropenia was observed for TL (18%) than for L (0%). Tipifarnib population pharmacokinetics were similar to previous studies, with no significant difference in trough letrozole concentrations between the TL and L groups.

Conclusions

Adding tipifarnib to letrozole did not improve objective response rate in this population of patients with advanced breast cancer.

Nur mit Berechtigung zugänglich

Clark GJ, Der CJ (1995) Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35:133–144PubMedCrossRef

Clark GJ, Kinch MS, Gilmer TM et al (1996) Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 12:169–176PubMed

Norgaard P, Law B, Joseph H et al (1999) Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 5:35–42PubMed

End DW, Smets G, Todd AV et al (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131–137PubMed

Kelland LR, Smith V, Valenti M et al (2001) Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7:3544–3550PubMed

Johnston SR, Hickish T, Ellis P et al (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21:2492–2499PubMedCrossRef

Nicholson RI, McClelland RA, Robertson JF, Gee JM (1999) Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6:373–387PubMedCrossRef

Simoncini T, Hafezi-Moghadam A, Brazil DP et al (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538–541PubMedCrossRef

Levin ER (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17:309–317PubMedCrossRef

10.

Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926–935PubMedCrossRef

11.

Johnston SR (2005) Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 11:889s–899sPubMed

12.

Gee JM, Harper ME, Hutcheson IR et al (2003) The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144:5105–5117PubMedCrossRef

13.

Martin LA, Head J, Pancholi S et al (2007) The farnesyl transferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in-vitro and in-vivo. Mol Cancer Ther (in press)

14.

Ellis CA, Vos MD, Wickline M et al (2003) Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 78:59–67PubMedCrossRef

15.

Doisneau-Sixou SF, Cestac P, Faye JC et al (2003) Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer 106:789–798PubMedCrossRef

16.

Long BJ, Liu G, Marrinan CH et al (2004) Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts. Proc Am Assoc Cancer Res 45:A3868

17.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

18.

Crul M, de Klerk GJ, Swart M et al (2002) Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20:2726–2735PubMedCrossRef

19.

Perez-Ruixo JJ, Piotrovskij V, Zhang S et al (2006) Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol 62:81–96PubMedCrossRef

20.

Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453–461PubMed

21.

Prendergast GC, Davide JP, deSolms SJ et al (1994) Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193–4202PubMed

22.

Miquel K, Pradines A, Sun J et al (1997) GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 57:1846–1850PubMed

23.

Sepp-Lorenzino L, Rosen N (1998) A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 273:20243–20251PubMedCrossRef

24.

Du W, Liu A, Prendergast GC (1999) Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 59:4208–4212PubMed

25.

Gutierrez MC, Detre S, Johnston S et al (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469–2476PubMedCrossRef

26.

Lipton A, Leitzel K, Ali SM et al (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104:257–263PubMedCrossRef

27.

Chan S, Scheulen ME, Johnston S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314–5322PubMedCrossRef

28.

Boulay A, Rudloff J, Ye J et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11:5319–5328PubMedCrossRef

29.

deGraffenried LA, Friedrichs WE, Russell DH et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059–8067PubMedCrossRef

30.

Baslega J, Roche H, Fumoleau P et al (2005) Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combinations with temsirolimus; a randomized 3-arm, phase 2 study. 28th annual San Antonio breast cancer symposium 94S:Abstract no. 1068

31.

Kaufman B (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC). European Society for Medical Oncology (ESMO) Congress 2006:Abstract no. LBA2

32.

Moulder SL, Sparano JA, Kazi A et al (2005) The farnesyltransferase inhibitor (FTI) tipifarnib inhibits FPTase in vivo and enhances the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer 28th annual San Antonio breast cancer symposium 94S:Abstract no. 5061

Titel: A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy
verfasst von: Stephen R. D. Johnston
Vladimir F. Semiglazov
George M. Manikhas
Dominique Spaeth
Gilles Romieu
David J. Dodwell
Andrew M. Wardley
Patrick Neven
Annick Bessems
Youn C. Park
Peter M. De Porre
Juan J. Perez Ruixo
Angela J. Howes
Publikationsdatum: 01.07.2008
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9726-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy